KRAS and pancreatic ductal adenocarcinoma: Conversely, USP9X has tumour suppressor functions via its genetic interaction with Kras. Mutations in KRAS are frequently found in pancreatic ductal adenocarcinoma (PDA), and expression of oncogenic KrasG12D mutation in mouse pancreatic tissue initiates the development of PDA.